Regenxbio RGNX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.39M-92.8% | $30.34M+43.0% | $29.73M+22.9% | $21.36M-4.2% | $89.01M+470% | ||
| $57.34M+8.0% | $59.61M+18.3% | $56.1M+3.1% | $59.5M+21.8% | $53.09M-3.2% | ||
| $21.31M+4.7% | $22.38M+11.6% | $20.25M+4.3% | $19.88M+5.5% | $20.35M+11.2% | ||
| $89.76M+16.7% | $87.97M+21.2% | $82.14M-4.8% | $84.64M+8.0% | $76.89M-3.3% | ||
| -$83.36M-787% | -$57.64M-12.2% | -$52.41M+15.6% | -$63.28M-12.9% | $12.13M+119% | ||
| -1,304%-1,318pp | -190%+52.2pp | -176.3%+80.3pp | -296.3%-44.9pp | 13.6%+422pp | ||
| $8.71M+1.6% | $12.28M+30.4% | $13.17M+1,506% | $10.99M+2,348% | $8.57M+334% | ||
| $2M-19.9% | $2.75M-71.2% | $3.62M+10.5% | $3.38M-2.6% | $2.5M+1.3% | ||
| -$6.69M-10.7% | -$9.51M-5,327% | -$9.53M-484% | -$7.59M-349% | -$6.04M-1,234% | ||
| -$90.05M-1,580% | -$67.15M-31.2% | -$61.94M-3.9% | -$70.87M-33.7% | $6.08M+110% | ||
| -1,408.6%-1,415pp | -221.3%+19.9pp | -208.3%+38.0pp | -331.8%-94.1pp | 6.8%+412pp | ||
| -$1.72-1,533% | -$1.30-30.0% | -$1.20-2.6% | -$1.38-31.4% | $0.12+109% | ||
| -$1.72-1,533% | -$1.30-30.0% | -$1.20-2.6% | -$1.38-31.4% | $0.12+109% | ||
| 52.4M+1.9% | 51.6M+4.2% | 51.7M+1.8% | 51.5M+1.7% | 51.4M+12.5% | ||
| 52.4M+2.1% | 51.6M+4.2% | 51.7M+1.8% | 51.5M+1.7% | 51.4M+12.3% | ||
| $11.07M+222% | $5.93M-6.2% | $5.73M-53.8% | $5.21M-50.8% | $3.44M-19.8% | ||
| -$36K-140% | -$54K+93.5% | -$65K-75.7% | -$45K-55.2% | -$15K-144% | ||
| $16K-36.0% | $18K-78.3% | $19K-24.0% | $21K-27.6% | $25K-32.4% | ||
| -$90.23M-1,589% | -$67.18M-30.8% | -$61.84M-6.8% | -$70.86M-36.2% | $6.06M+110% | ||
| $2M-19.9% | $2.75M-71.2% | $3.62M+10.5% | $3.38M-2.6% | $2.5M+1.3% | ||
| -$183K-771% | —— | $98K-94.2% | $12K-98.8% | -$21K-102% | ||
| -$183K-771% | —— | $98K-94.2% | $12K-98.8% | -$21K-102% | ||
| —— | —— | —— | —— | —— | ||
| $6.39M-92.8% | $30.34M+43.0% | $29.73M+22.9% | $21.36M-4.2% | $89.01M+470% | ||
| -$83.36M-787% | -$57.64M-12.2% | -$52.41M+15.6% | -$63.28M-12.9% | $12.13M+119% | ||
| -$79.51M-594% | -$53.77M-13.6% | -$48.53M+16.5% | -$59.37M-14.2% | $16.08M+127% | ||
| -$79.51M-594% | -$53.77M-13.6% | -$48.53M+16.5% | -$59.37M-14.2% | $16.08M+127% | ||
| -1,243.6%-1,262pp | -177.2%+45.9pp | -163.2%+77.0pp | -278%-44.8pp | 18.1%+400pp | ||
| -$83.36M-787% | -$57.64M-12.2% | -$52.41M+15.6% | -$63.28M-12.9% | $12.13M+119% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regenxbio's revenue?
- Regenxbio (RGNX) generated $87.8M in revenue over the trailing twelve months, down 44.0% year over year.
- Is Regenxbio profitable?
- Regenxbio is not currently profitable: it reported a net loss of $290.0M over the trailing twelve months, a -330.2% net margin.
- What are Regenxbio's profit margins?
- Gross margin is 59.7% and operating margin is -292.3%, with a -330.2% net margin.
- What is Regenxbio's earnings per share?
- Regenxbio's diluted EPS over the trailing twelve months is $-5.60.
- Where does Regenxbio's income statement data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
